Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746 million) in total during 2025. As of June 27th, 2025, Novonesis has purchased an accumulated 1,729,099 shares with a transaction value of DKK 745,2 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025.
Please read the full announcement in PDF.
Attachment
January 16, 2026 16:05 ET | Source: Context Therapeutics Inc. PHILADELPHIA, Jan. 16, 2026 (GLOBE…
January 16, 2026 16:05 ET | Source: CAMP4 Therapeutics CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE…
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am…
NEURODYNE DROPS INTRODUCED AS A COGNITIVE WELLNESS SUPPLEMENT SUPPORTING HEALTHY MEMORY, FOCUS, AND MENTAL CLARITY…
New York City, NY, Jan. 17, 2026 (GLOBE NEWSWIRE) -- OPTIVELL INTRODUCED AS A NEW…
SUGAR CLEAN DROPS ANNOUNCED AS A NEW SUPPLEMENT SUPPORTING HEALTHY BLOOD SUGAR AND METABOLIC WELLNESS…